# Cagrilintide

CagriSema (with semaglutide) · AM833

https://graded.pl/en/substances/cagrilintide · Checked: Not yet

Preliminary version. The editors have not finished checking this card, and grades may change.

A substance that mimics amylin, a fullness hormone. Still being studied, alone and with semaglutide. Not approved in the EU or US.

> This site is for information and education only. It does not promote or encourage the use or purchase of the substances described and is not medical advice. Many are not authorised as medicines and their safety has not been established. We sell nothing and have no ties to sellers. For health decisions, consult a doctor.

## Short answers

### Does cagrilintide work?

A substance that mimics amylin, a fullness hormone. Still being studied, alone and with semaglutide. Not approved in the EU or US. Fat loss: grade B, effect in studies. Weight fell 6.0% to 10.8%, and 3.0% on placebo, in an early study. In a large study the mix with semaglutide reached 20.4% against 3.0%, but that is a result for the mix.

### Is Cagrilintide legal?

PL: No approval. The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly. EU: No approval. The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026). US: No approval. The FDA drug register has no such medicine.

### Is cagrilintide banned in sport?

May be banned, WADA 2026. It is not on the WADA list, but WADA also bans substances that no health authority has approved, so it may be banned.

### Is Cagrilintide safe?

Little data. There are early studies and a large study with semaglutide. Stomach and bowel problems were common in both. No approval yet.

## What studies show

| | | | |
|---|---|---|---|
| Fat loss | B | Effect in studies | Weight fell 6.0% to 10.8%, and 3.0% on placebo, in an early study. In a large study the mix with semaglutide reached 20.4% against 3.0%, but that is a result for the mix. |

## Studies we have read

- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. (The New England journal of medicine 2025; Random groups) https://pubmed.ncbi.nlm.nih.gov/40544433/
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. (Lancet (London, England) 2021; Random groups) https://pubmed.ncbi.nlm.nih.gov/34798060/

## Is it legal

- PL: No approval. The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly. https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx (Checked: Not yet)
- EU: No approval. The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026). https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx (Checked: Not yet)
- US: No approval. The FDA drug register has no such medicine. https://www.accessdata.fda.gov/scripts/cder/daf/ (Checked: Not yet)

## Doping

May be banned, WADA 2026. https://zoek.officielebekendmakingen.nl/trb-2026-25.html

## How much research exists

- Scientific papers: 124
- Studies with random groups: 15
- Registered studies in people: 44
- These are search results. A count shows how much exists, not how good the studies are. 1 Nov 2026.

---
Open data: CC BY 4.0, https://creativecommons.org/licenses/by/4.0/